Detalles de la búsqueda
1.
Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer.
J Oncol Pharm Pract
; 30(2): 404-407, 2024 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37899576
2.
Avascular necrosis during alectinib treatment: Case report.
J Oncol Pharm Pract
; 29(1): 242-245, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35635227
3.
Prognosis-related novel immunostaining pattern for programmed cell death ligand 1 and prognostic value of tumour-infiltrating lymphocytes in triple-negative breast cancer.
Pol J Pathol
; 74(2): 65-74, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37728465
4.
The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study.
Anticancer Drugs
; 33(7): 663-670, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35703239
5.
Re-use of erlotinib in a patient using osimertinib after erlotinib, case report.
J Oncol Pharm Pract
; 28(1): 211-214, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34074173
6.
Ado-trastuzumab emtansine associated spider telangiectasia.
J Oncol Pharm Pract
; 28(4): 986-988, 2022 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-35040682
7.
Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.
Tumour Biol
; 37(3): 3665-73, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26462835
8.
A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
Medicine (Baltimore)
; 103(21): e37972, 2024 May 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-38787994
9.
Treatment outcomes and prognostic factors in patients with driver mutant non-small cell lung cancer and de novo brain metastases.
Sci Rep
; 14(1): 5820, 2024 03 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-38461209
10.
Comparison of Alectinib/Crizotinib Data in First-Line Therapy in Patients with Anaplastic LymphomakinasePositive Nonsmall Cell Lung Carcinoma with Poor Prognostic Features for Alectinib.
Thorac Res Pract
; 24(4): 180-185, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-37485706
11.
Prognostic and predictive role of liquid biopsy in lung cancer patients.
Front Oncol
; 13: 1275525, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38304031
12.
Is there any prognostic significance in pleural involvement and/or effusion in patients with ALK-positive NSCLC?
J Cancer Res Clin Oncol
; 149(14): 13271-13277, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37480524
13.
Real-life comparison of afatinib and erlotinib in non-small cell lung cancer with rare EGFR exon 18 and exon 20 mutations: a Turkish Oncology Group (TOG) study.
J Cancer Res Clin Oncol
; 149(2): 865-875, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-35381885
14.
Predictive role of neutropenia under crizotinib treatment in ALK-rearranged nonsmall cell lung cancer patients: A single-institution retrospective analysis.
Indian J Cancer
; 59(2): 251-256, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35017371
15.
Evaluation of Treatment Efficacy of Tyrosine Kinase Inhibitors in Rare Single EGFR Exon 21 L861Q Mutation: Single Center Experience.
Turk Thorac J
; 23(4): 290-295, 2022 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-35848437
16.
PDL-1 Expression and Survival in Metastatic Non-small Cell Lung Cancer Patients Who Received Chemotherapy as First-Line Treatment.
Turk Thorac J
; 23(1): 45-51, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35110200
17.
Systemic Immune Inflammation Index as a Key Marker of Survival and Immune-related Adverse Events in Immune Checkpoint Inhibitor Therapy.
J Coll Physicians Surg Pak
; 32(8): 996-1003, 2022 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-35932122
18.
Crizotinib efficacy and safety in patients with advanced NSCLC harboring MET alterations: A real-life data of Turkish Oncology Group.
Medicine (Baltimore)
; 101(50): e32368, 2022 Dec 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-36550824
19.
The effectiveness of cetuximab and panitumumab when combined with FOLFIRI in second-line treatment of KRAS wild type metastatic colorectal cancers. Single centre experience.
J Chemother
; 33(3): 180-186, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33349195
Resultados
1 -
19
de 19
1
Próxima >
>>